Stock SPRY ARS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
8.7 USD +1.16% Intraday chart for ARS Pharmaceuticals, Inc. +2.35% +58.76%
Apr. 18 ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
Apr. 18 ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
GL
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp
CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing
MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy
MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy
DJ
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
GL
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
AQ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)
CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index
CI
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day
AQ
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
GL
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
GL
North American Morning Briefing : Stock Futures -2-
DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6
MT
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. News ARS Pharmaceuticals, Inc.